March 20, 2026

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Classification of Unit-V of Apitoria Pharma Limited, a wholly owned subsidiary of the Company as VAI by the US FDA – Reg.,

Ref: Our letter dated December 12, 2025

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected Unit-V, an API manufacturing facility, of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at Industrial Development Area, Chemical Zone, Pashamylaram Village, Patancheru Mandal, Sangareddy District, 502307, Telangana from December 01 to December 12, 2025. At the end of the inspection, a 'Form 483' was issued with 03 observations.

The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as 'Voluntary Action Indicated' (VAI) and this inspection is now "closed".

Please take the above information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.03.20 09:45:29 +05'30'

B. Adi Reddy
Company Secretary